Tevogen Bio (NASDAQ:TVGN) Rating Lowered to “Strong Sell” at Wall Street Zen

Tevogen Bio (NASDAQ:TVGN) was downgraded by Wall Street Zen to a “strong sell” rating in a research report issued to clients and investors on Saturday.

TVGN has been the subject of a number of other reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tevogen Bio in a report on Wednesday, January 21st. D. Boral Capital lowered Tevogen Bio from a “buy” rating to a “hold” rating in a research note on Wednesday, March 4th. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Tevogen Bio currently has an average rating of “Reduce” and an average target price of $100.00.

Tevogen Bio Stock Down 1.7%

Shares of NASDAQ TVGN opened at $5.22 on Friday. The stock has a market capitalization of $21.14 million, a price-to-earnings ratio of -0.55 and a beta of -0.76. Tevogen Bio has a 52 week low of $4.89 and a 52 week high of $75.50. The firm has a 50-day moving average price of $12.65 and a 200 day moving average price of $22.95.

Hedge Funds Weigh In On Tevogen Bio

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bridgeway Capital Management LLC grew its position in shares of Tevogen Bio by 66.7% in the third quarter. Bridgeway Capital Management LLC now owns 82,500 shares of the company’s stock valued at $65,000 after purchasing an additional 33,000 shares during the last quarter. Goldman Sachs Group Inc. raised its position in shares of Tevogen Bio by 126.0% during the 4th quarter. Goldman Sachs Group Inc. now owns 273,694 shares of the company’s stock worth $91,000 after purchasing an additional 152,572 shares during the last quarter. Finally, Deutsche Bank AG raised its position in shares of Tevogen Bio by 304.1% during the 4th quarter. Deutsche Bank AG now owns 173,734 shares of the company’s stock worth $57,000 after purchasing an additional 130,738 shares during the last quarter.

About Tevogen Bio

Tevogen Bio plc (NASDAQ:TVGN) is a clinical-stage biotechnology company focused on developing personalized natural killer (NK) cell immunotherapies for oncology and severe viral diseases. Leveraging proprietary induced pluripotent stem cell (iPSC) and donor-derived NK cell platforms, Tevogen Bio aims to create off-the-shelf cell therapy products that offer scalable and cost-efficient treatment options. The company’s lead candidate, TVGN-484, is an allogeneic NK cell therapy in clinical trials for relapsed or refractory acute myeloid leukemia (AML).

In addition to its lead program in AML, Tevogen Bio’s pipeline includes preclinical NK cell candidates directed against hematological malignancies, solid tumors and viral infections.